STOCK TITAN

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

Lantheus (NASDAQ: LNTH) announced that John Wiggins, Vice President, External Manufacturing, will join a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.

(Neutral)
(Neutral)
Tags

Lantheus (NASDAQ: LNTH) announced that John Wiggins, Vice President, External Manufacturing, will join a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3. A live webcast and 30-day replay will be available via the company’s investor website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus May 27 session
-0.97% close to close Open Argus
Details

News Market Reaction – LNTH

In the May 27 session, LNTH declined 0.97%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an investor-focused appearance, with Lantheus presenting at the William...
Analysis

This announcement highlights an investor-focused appearance, with Lantheus presenting at the William Blair 46th Annual Growth Stock Conference on June 3. It continues a steady cadence of visibility events following strong Q1 2026 financials and multiple scientific data presentations. Investors may monitor management’s commentary during the fireside chat for any updates related to guidance, commercial launches, or key regulatory milestones that build on the company’s recent disclosures.

Key Figures

Q1 2026 revenue: $377.3M Q1 2026 GAAP net income: $118.4M Q1 2026 GAAP EPS: $1.80 +5 more
Q1 2026 revenue
$377.3M
Reported in first quarter 2026 financial results
Q1 2026 GAAP net income
$118.4M
Reported in first quarter 2026 results
Q1 2026 GAAP EPS
$1.80
Fully diluted EPS versus $1.02 a year earlier
Q1 2026 adjusted EPS
$1.46
Adjusted earnings per share for Q1 2026
Cash and equivalents
$498.6M
Balance as of Q1 2026, including $31.4M from SPECT divestiture
2026 revenue guidance
$1.4B–$1.45B
Reaffirmed full-year 2026 revenue outlook
2026 adjusted EPS guidance
$5.00–$5.25
Reaffirmed full-year 2026 adjusted EPS outlook
Market capitalization
$6,514,514,565
Pre-news market value based on latest provided data

Historical Context

5 past events · Latest: May 21
5 events
  1. May 21

    Radiodiagnostic data

    24h Move
    -1.7%

    Announced new PSMA-PET and 18F-GP1 radiodiagnostic data presentations.

  2. May 19

    ASCO data presentations

    24h Move
    -0.6%

    Detailed new radiopharmaceutical data to be presented at ASCO 2026.

  3. May 07

    Q1 2026 earnings

    24h Move
    +5.6%

    Reported strong Q1 results, FDA approval of PYLARIFY TruVu, reaffirmed guidance.

  4. Apr 23

    Earnings call notice

    24h Move
    -0.1%

    Announced schedule and access details for Q1 2026 earnings call.

  5. Mar 17

    PDUFA date extension

    24h Move
    -0.3%

    Disclosed three-month FDA PDUFA extension for LNTH-2501 to June 29, 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.

To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Lantheus (NASDAQ: LNTH) present at the William Blair 46th Annual Growth Stock Conference?

Lantheus will participate in a fireside chat at 12:10 p.m. ET on Wednesday, June 3. According to Lantheus, the session is part of the William Blair 46th Annual Growth Stock Conference for investors and analysts.

Who will represent Lantheus (NASDAQ: LNTH) at the William Blair 46th Annual Growth Stock Conference?

John Wiggins, Vice President, External Manufacturing, will represent Lantheus at the conference. According to Lantheus, he will take part in a scheduled fireside chat focused on the company’s radiopharmaceutical business and operations.

How can investors access the Lantheus (NASDAQ: LNTH) webcast from the William Blair conference?

Investors can access the live Lantheus webcast by visiting the Investors section of the company’s website. According to Lantheus, the William Blair conference fireside chat will be streamed there at the scheduled time.

Will a replay of the Lantheus (NASDAQ: LNTH) William Blair conference presentation be available?

Yes, a replay of the Lantheus conference webcast will be available on the company’s website. According to Lantheus, investors can access the replay for at least 30 days after the live presentation.

What is the focus of Lantheus (NASDAQ: LNTH) as it presents at the William Blair conference?

Lantheus describes itself as a leading radiopharmaceutical-focused company helping clinicians Find, Fight, and Follow disease. According to Lantheus, the conference appearance showcases its commitment to improving patient outcomes through advanced diagnostic and therapeutic solutions.

Keep reading